Sentaur Biosciences
Pioneering Precision Therapeutics for Senescence Driven Diseases
Company Overview
Snapshot
Founded in March 2018 by Valery Krizhanovsky, Sentaur Biosciences operated with 1–10 employees. The company secured funding across three rounds from M Ventures and ExploreBio. Sentaur Biosciences ceased operations in March 2024.
Business overview
Sentaur Biosciences is a biotech company focused on senescence biology, dedicated to discovering and developing breakthrough treatments for debilitating age-related diseases. The company leverages a proprietary library of distinct senescent cell surface proteins, licensed from the laboratory of Prof. Valery Krizhanovsky, to target diseases involving senescent cell burden, with an initial focus on oncology and future expansion into age-related conditions. Sentaur Biosciences operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, aiming to develop precision therapeutics.
Log in to access full profile ›Company Intelligence Q&A
- What is Sentaur Biosciences' primary focus?
- Sentaur Biosciences focuses on senescence biology, discovering and developing breakthrough treatments for debilitating age-related diseases, with an initial emphasis on oncology.
- Who founded Sentaur Biosciences?
- Sentaur Biosciences was founded by Valery Krizhanovsky in March 2018.
- What is the status of Sentaur Biosciences?
- Sentaur Biosciences is non-active and ceased operations in March 2024.
- What technology does Sentaur Biosciences utilize?
- Sentaur Biosciences utilizes a library of distinct senescent cell surface proteins, discovered through high-throughput proteomic analysis and licensed from the laboratory of Prof. Valery Krizhanovsky.
- When did Sentaur Biosciences receive its first disclosed funding?
- Sentaur Biosciences received its first disclosed funding in June 2018 from M Ventures and ExploreBio.